Recent news on Ropinirole

Controlled-Release Ropinirole Improves Quality of Life for ...  -  May 7, 2007
DG NewsIn the 12-week, double-blind, placebo-controlled study Dr. Ziman and colleagues assigned 189 patients to 0.5 to 6.0 mg/day ropinirole CR and 195 patients to

Ropinirole Improves Mood, Reduces "Off" Time in Parkinson's ...  -  May 3, 2007
DG NewsIn the treatment cohort (n = 201) ropinirole was titrated upwards from 2 mg/day to a maximum dose of 24 mg/day over the course of 24 weeks.

International Approvals: Lipitor, Requip LP, Avastin  -  Apr 30, 2007
Medscape (subscription)The French regulatory authority Agence Française de Sécurité Sanitaire des Produits de Santé has approved ropinirole HCl prolonged release tablets for the

GeoMatrix technology develops another new drug formulation  -  May 17, 2007
BiopharmaReporter.com,...extended release formulation, using GeoMatrix technology, of GlaxoSmithKline's (GSK) drug Requip (ropinirole) for the treatment of Parkinson's disease.

FDA approves Schwarz Pharma's Neupro for Parkinsons  -  May 11, 2007
Pharma Times (subscription),...it failed to show non-inferiority to GlaxoSmithKline's rival product Requip (ropinirole), "hence we expect it will not be as successful as that drug."

Skyepharma says receives French approval for Parkinson's disease ...  -  Apr 23, 2007
Forbes,LONDON (Thomson Financial) - Skyepharma PLC said it has received regulatory approval in France for Parkinson's disease drug ropinirole prolonged release

SkyePharma PLC - Once-Daily REQUIP LP Extended-Release Tablets ...  -  Apr 23, 2007
PharmaLive.com (press release),The new prolonged release tablet of ropinirole is taken once daily, and is indicated for the treatment of Parkinson's disease (PD).

Skyepharma PLC - Once-Daily Requip (ropinirole HCl) XL 24-Hour ...  -  Apr 13, 2007
PharmaLive.com (press release),On 3 April 2007, GlaxoSmithKline announced positive results of the Ropinirole 24-Hour Efficacy and Safety Evaluation in PD-Adjunct (EASE-PD Adjunct) study,

Ropinirole reduces "off" time in Parkinson's  -  Apr 4, 2007
News-Medical.net,Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which Parkinson's symptoms

Ropinirole Prolonged-Release Reduces Parkinson's 'Off' Time  -  Apr 2, 2007
MedPage Today,Explain to patients who ask that ropinirole is a non-ergot dopamine agonist approved for treatment of Parkinson's disease and restless legs syndrome.

Once daily, extended-release ropinirole improves Parkinson’s ...  -  Apr 3, 2007
WebWire (press release),The Ropinirole 24-Hour Prolonged Release Randomized, Controlled Study in Advanced Parkinson Disease (EASE-PD Adjunct Study) results, published in the April

GlaxoSmithKline: Ropinirole improves Parkinson's symptoms  -  Apr 2, 2007
MarketWatch...said its once daily, extended-release ropinirole medication improves symptoms in patients with Parkinson's Disease. Parkinson's Disease is a chronic disease

Medication Ups Quality of Life for Parkinson’s  -  Apr 4, 2007
PsychCentral.com,Researchers discover Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release, reported significant reduction in troublesome

Drug Reduces Daily 'Off' Time For Parkinson Patients  -  Apr 2, 2007
Science Daily (press release)Science Daily — Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which

Drug Cuts 'Off' Time for Parkinson's Patients  -  Apr 5, 2007
Forbes,Half the patients took 24-hour prolonged release ropinirole and levodopa for six months, while the other half took a placebo and levodopa.

Drug Cuts 'Off' Time for Parkinson's Patients  -  Apr 5, 2007
CBC News,THURSDAY, April 5 (HealthDay News) - Taking 24-hour prolonged release ropinirole significantly reduced daily "off" time that Parkinson's disease patients

GlaxoSmithKline: reformulation of Parkinson's drug set for success  -  Apr 13, 2007
Pharmaceutical Business ReviewA once-daily formulation of GlaxoSmithKline's Parkinson's disease drug Requip (ropinirole) has been filed for approval with the FDA.

Drug Reduces Daily "Off" Time for Parkinson Patients  -  Apr 3, 2007
DG NewsFor the study, half of the group took the prolonged release version of the drug ropinirole, called ropinirole 24-hour, and levodopa for six months.

Parkinson's drug reduces daily "off" time  -  Apr 3, 2007
Pharmaceutical Business ReviewParkinson's disease patients taking the extended-release ropinirole medication significantly reduced their daily "off" time in which Parkinson's symptoms

Drug offers longer Parkinson's relief, study says  -  Apr 5, 2007
Monterey County Herald,In the study, 393 patients who were having problems managing their symptoms with L-dopa alone were given the experimental formulation of ropinirole once a

Market Report -- In Play (SKYE)  -  Apr 13, 2007
MSN MoneySkyepharma announces once-daily REQUIP (ropinirole HCl) XL 24-hour extended-release tablets accepted for filing by US FDA Co announces that the US FDA has

US regulatory boost for Skye  -  Apr 13, 2007
Hemscott,Ropinirole is already being marketed in an immediate release format as REQUIP for Parkinson's but need to be administered three times a day.

Parkinson's disease better controlled with prolonged-release drug  -  Apr 2, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - The 24-hour prolonged-release formulation of ropinirole (ropinirole 24-hour) is a safe and effective treatment for patients with

Skyepharma says US FDA accepts GSK filing for REQUIP XL tablets UPDATE  -  Apr 13, 2007
Forbes,...for REQUIP XL extended-release tablets, the proposed brand name for a once-daily formulation of ropinirole for treating Parkinson's disease.

Skyepharma says US FDA accepts GSK filing for REQUIP extended ...  -  Apr 13, 2007
Forbes,GlaxoSmithKline PLC, for REQUIP XL extended-release tablets, the proposed brand name for ropinirole formulation for treating Parkinson's disease.

GlaxoSmithKline files updated Requip  -  Apr 13, 2007
MoneyWeek (Subscription),Requip is currently administered three times a day, but Requip, a formulation of ropinirole for treating Parkinson's disease, has been designed to provide a

Stocks to Watch: Google, GlaxoSmithKline, Pfizer, Tenet, Tribune  -  Apr 3, 2007
Minyanville.com,GlaxoSmithKline Plc (GSK) said its once-daily, extended-release ropinirole medication improves symptoms in patients with Parkinson's disease.

Healthy Black Hair: Step-by-Step Instructions for Growing Longer ...  -  Apr 18, 2007
Science Daily (press release)...alopecia (baldness) while being treated with the dopamine agonists pramipexole or ropinirole found that the hair loss stopped after the drugs were .

Raising awareness of Parkinson's disease  -  Apr 17, 2007
News Shopper,The father-of-one is now taking the drug Ropinirole and visits his GP every six months for a review of how the disease is progressing.

Skye formulation accepted for GSK drug  -  Apr 16, 2007
In-PharmaTechnologist.com,...and Drug Administration (FDA) has accepted a filing for the extended release formulation of partner GlaxoSmithKline's (GSK) drug Requip (ropinirole).

European stocks close higher  -  Apr 13, 2007
International Herald Tribune,Requip XL is the proposed brand name for a formulation of ropinirole for treating Parkinson's disease. Skyepharma's shares rose 1 percent in London.

Europe ends higher as oil shares hum  -  Apr 13, 2007
MarketWatchRequip XL is the proposed brand name for a formulation of ropinirole for treating Parkinson's disease. Skyepharma's shares rose 1% in London.

On the Move:Shell, SAP, Sanofi  -  Apr 13, 2007
BusinessWeekSkyepharma said the US FDA has accepted for filing the application by the company, which is its partner, for Requip, a once-daily formulation of ropinirole

DJ MARKET COMMENT: European Stocks Led Higher By Glaxo  -  Apr 13, 2007
Onet.pl,Requip XL is the proposed brand name for a formulation of ropinirole for treating Parkinson's disease. Skyepharma shares rose 3.1% in London.

Help For Restless Legs  -  Apr 13, 2007
WFtv.com,The newest medications of this kind, pramipexole (Mirapex) and ropinirole (Requip), target the motivation, emotion, and reward centers of the brain.

More on quinine and leg cramps  -  Apr 13, 2007
Fort Wayne News Sentinel,COMMENT: Mirapex (pramipexole) and Requip (ropinirole) are prescribed to treat restless legs syndrome. They appear to work by enhancing the activity of the

Skyepharma says US FDA accepts GSK filing for REQUIP XL tablets UPDATE  -  Apr 13, 2007
Euro2day,...for REQUIP XL extended-release tablets, the proposed brand name for a once-daily formulation of ropinirole for treating Parkinson''s disease.

Readers tell what works for restless legs  -  Apr 12, 2007
SunHerald.com,Comment: Mirapex (pramipexole) and Requip (ropinirole) are prescribed to treat restless legs syndrome. They appear to work by enhancing the activity of the

Restless leg syndrome  -  Apr 9, 2007
GMTV,Research shows that medicines called dopamine agonists (such as ropinirole and pergolide) have most success in treating RLS.

FDA yanks Parkinson's drug from market  -  Mar 30, 2007
CNNMoney.comOther dopamine agonists include GlaxoSmithKline's (Charts) Requip, or ropinirole, and Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex, or pramipexole.

Parkinson's drug 'pulled from US market'  -  Mar 29, 2007
Sydney Morning Herald,Other dopamine agonists include GlaxoSmithKline's Requip, or ropinirole, and Boehringer Ingelheim Pharmaceuticals, Inc's Mirapex, or pramipexole.

Parkinson's drug pulled from US market: FDA  -  Mar 30, 2007
Business Insurance,Other dopamine agonists include GlaxoSmithKline's Requip, or ropinirole, and Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex, or pramipexole.

FDA: Parkinson's Drug Pulled from Market  -  Mar 30, 2007
WETM-TV,Other dopamine agonists include GlaxoSmithKline's Requip, or ropinirole, and Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex, or pramipexole.

Therapy for restless legs may trigger compulsive gambling  -  Feb 11, 2007
News-Medical.net,Speculation is that the gambling problems are emerging now because the newer generation of dopamine agonists -- including pramipexole and ropinirole -- are

Restless Leg Drug may Cause Compulsive Gambling  -  Feb 12, 2007
Lex 18,The newest medications of this kind, pramipexole (Mirapex) and ropinirole (Requip), target the motivation, emotion, and reward centers of the brain.

Gambling problem can affect restless legs patients  -  Jan 31, 2007
Scientific AmericanSome of these drugs commonly used for one or both conditions include Requip (generic name ropinirole), Mirapex (pramipexole) and Sinemet (levodopa plus

'Restless legs' drugs linked to gambling  -  Feb 8, 2007
United Press International8 (UPI) -- Drugs taken for "restless legs syndrome," including Requip (ropinirole) and Mirapex (pramipexole), might be linked to high-roller gambling.

Compulsive Gambling a possible side-effect of Restless Leg ...  -  Feb 14, 2007
ScienceBlogsResearchers at Mayo identified 3 patients who developed compulsive gambling after being treated with either pramipexole or ropinirole -- two drugs used to

Drug may cause compulsive gambling  -  Feb 9, 2007
Jackpot.co.uk,Pramipemole and ropinirole target the receptors in the brain responsible for motivation, emotion and reward behaviours. The Mayo Clinic also believes that

Late-Stage RLS Drug Lands XenoPort $640M GSK Deal  -  Feb 8, 2007
BioWorld Online,The company's dopamine agonist, Requip (ropinirole), was approved as the first drug to treat patients with moderate to severe RLS, a neurological condition

A Case of Mania Following the Use of Pramipexole  -  Jan 31, 2007
Am J Psychiatry (subscription)Singh A, Althoff R, Martineau RJ, Jacobson J: Pramipexole, ropinirole, and mania in Parkinson’s disease. Am J Psychiatry 2005; 162:814–815 [Free Full Text]

Requip, ropinirole treatment for restless legs syndrome  -  Dec 20, 2006
SpiritIndia,Last Super Bowl, a TV commercial lauded the power of Requip (ropinirole), the first drug approved to treat restless leg syndrome, a condition whose

Tweaking The Treatment For Restless Legs  -  Dec 26, 2006
Science Daily (press release)Science Daily — Last Super Bowl, a TV commercial lauded the power of Requip (ropinirole), the first drug approved to treat restless leg syndrome,

Quick takes on health  -  Jan 10, 2007
Rochester Democrat and Chronicle,Requip (ropinirole) and Mirapex (pramipexole), which are heavily advertised, may seem like simple solutions to the creepy-crawly leg sensations that

12 Million Can't Sleep, Can't Sit With Restless Legs Syndrome  -  Jan 9, 2007
ABC NewsFor decades, Jefferson has searched to find the right medicine, and when doctors prescribed Requip (ropinirole) — the drug most commonly prescribed for RLS

2 Parkinson's drugs tied to heart woes  -  Jan 4, 2007
Los Angeles Times,...known because of the development of newer dopamine agonists, including pramipexole and ropinirole, said Dr. Fernando Pagan of Georgetown University.

Heart-Valve Disease Linked to Two Parkinson's Drugs  -  Jan 4, 2007
MedPage Today,...bromocriptine or Dopergine (lisuride) or with dopamine agonists that are not derived from ergot, Requip (ropinirole) or Mirapex (pramipexole),

Two Parkinson's drugs implicated as cause of valvular dysfunction  -  Jan 3, 2007
TheHeart.Org,...had not been on either drug or any other dopamine agonist—which in this analysis could have included bromocriptine, lisuride, pramipexole, or ropinirole.

Ex-teacher battles back from slots addiction  -  Dec 21, 2006
Daily Mail - Charleston,Requip, also known as Ropinirole, and other drugs used to treat Parkinson's have been linked to compulsive gambling. "I was raised in a home without alcohol

Tweaking The Treatment For Restless Legs  -  26 Dec 2006
Medical News Today (press release),Last Super Bowl, a TV commercial lauded the power of Requip (ropinirole), the first drug approved to treat restless leg syndrome, a condition whose

Ex-teacher battles back from slots addiction  -  Dec 21, 2006
Daily Mail - Charleston,Requip, also known as Ropinirole, and other drugs used to treat Parkinson's have been linked to compulsive gambling. "I was raised in a home without alcohol

Using Pramipexole in Neuropsychiatry: A Cautionary Note  -  Nov 29, 2006
Journal of Neuropsychiatry (subscription)Etminan M, Gill S, Samii A: Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis.

Syndrome affects legs, causes sleep loss  -  Nov 27, 2006
Midland Daily News (subscription),The drug ropinirole (Requip) -- which Burns uses -- has been approved by the FDA for the treatment of moderate to severe restless legs syndrome.

NovaDel Pharma: Promising New Technology Makes It a Buy  Nov 6, 2006
Zanaflex is a trademark of Acorda Therapeutics (ACOR). Requip - Ropinirole spray for Parkinson's disease, currently in pre-clinical characterization. ... -Seeking Alpha, Switch From Oral Dopamine Agonist to Patch Therapy Appears Simple ...  Oct 11, 2006
..."In this trial, an overnight switch from ropinirole, pramipexole or cabergoline to rotigotine was safe and well tolerated, without exacerbating Parkinson's ... -DG News NovaDel Reports Fourth Quarter and Full Year Fiscal 2006 Financial ...  Oct 30, 2006
The addition of two oral spray drug candidates to our pipeline, tizanidine oral spray for spasticity and ropinirole oral spray for Parkinson's disease. ... -PharmaLive.com (press release), Study Reveals Investigational 24-Hour Formulation of Ropinirole ...  Sep 12, 2006
RESEARCH TRIANGLE PARK, NC -- September 12, 2006 -- The addition of investigational Requip® (ropinirole HCl) extended-release tablets to Parkinson's patients ... -DG News

New Study Reveals Investigational 24-hour Formulation of Requip ...  Sep 5, 2006
4, 2006 — The addition of investigational Requip® (ropinirole HCl) extended-release tablets to Parkinson’s patients existing therapy delayed “off ... -PharmaLive.com

NovaDel Announces Two CNS Oral Spray Drug Candidates in its ...  Sep 13, 2006
...are focused on treating disorders of the central nervous system (CNS), with Tizanidine Oral Spray (formerly NVD 422) for spasticity and Ropinirole Oral Spray ... -PharmaLive.com

Insomnia Agents Claimed 82% of Sales for the Sleeping Disorders ...  Sep 4, 2006
In 2005, ropinirole (GlaxoSmithKline's Requip) became the first agent to receive approval for treatment of restless legs syndrome (RLS). ... -Genetic Engineering News

New Study Reveals Investigational 24-Hour Formulation of Requip(R) ...  Sep 4, 2006
The addition of investigational Requip(R) (ropinirole HCl) extended-release tablets to Parkinson's patients existing therapy delayed "off" time -- a well-known ... -International News Service

New Study Reveals Investigational 24-Hour Formulation of Requip(R) ...  Sep 4, 2006
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- September 04, 2006 -- The addition of investigational Requip® (ropinirole HCl) extended-release tablets to ... -Market Wire

Schwarz Pharma's Neupro® (rotigotine Transdermal Patch) Offers ...  Sep 6, 2006
Open-label clinical trial results presented at the EFNS showed that patients treated with a dopamine agonist (eg ropinirole, pramipexole) were able to easily ... -Medical News Today

GlaxoSmithKline Says Requip Tablets Reduced "Off" Time For ...  Sep 4, 2006
...news | PowerRating) said that new study reveals investigational 24-hour formulation of requip(R | charts | news | PowerRating) (ropinirole hcl) tablets reduced ... -Trading Markets

Using Pramipexole in Neuropsychiatry: A Cautionary Note  -  Nov 29, 2006
Journal of Neuropsychiatry (subscription)Etminan M, Gill S, Samii A: Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis.

Syndrome affects legs, causes sleep loss  -  Nov 27, 2006
Midland Daily News (subscription),The drug ropinirole (Requip) -- which Burns uses -- has been approved by the FDA for the treatment of moderate to severe restless legs syndrome.

Restless legs relief  Aug 19, 2006
Ropinirole, a drug for Parkinson’s, is highly effective for RLS (which is not connected with Parkinson’s) when administered in low doses. ... -Times Online

Glaxo's cure for 'restless legs' was an unlicensed drug  Aug 5, 2006
The website of the Ekbom Support Group said the GSK drug ropinirole, marketed as Adartrel, was effective to treat restless legs although the drug had no ... -The Sunday Times

Long-Term Study Of Ropinirole In Restless Legs Syndrome  Jun 24, 2006
This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with ... -Community Dispatch

Dopamine Drug Leads To New Neurons And Recovery Of Function In Rat ...  Jul 6, 2006
7-OH-DPAT is not used in humans, but its effects on dopamine receptors are similar to the drugs pramipexole and ropinirole, which are approved to treat PD. ... -Medical News Today



Long-Term Ropinirole for Restless Legs Syndrome Tolerable ...  May 5, 2006
CHICAGO, IL -- May 5, 2006 -- Long-term use of the dopamine agonist ropinirole appears to be generally well tolerated in patients with restless legs syndrome ... - DG News

Disease mongering Restless Legs Syndrome: A case study of how the ...  May 11, 2006
...beginning with press releases about presentations at the American Academy of Neurology meeting describing the early trial results of using ropinirole (a drug ... - Newstarget.com

Parkinson Disease Guidelines Aid Diagnosis, Management  May 9, 2006
Also recommended, but backed by less robust evidence, are the dopamine agonists ropinirole, pramipexole, and pergolide, and another catechol-O ... - Journal of American Medical Association (subscription)

Financial: Glaxo denies pushing 'lifestyle' treatments: 'Restless ...  Apr 28, 2006
...authors of the report highlighted the "restless legs" syndrome, described by GSK as "common yet unrecognised" when it launched its Ropinirole treatment last ... - Therapeutics Daily (subscription)

Restless Legs Syndrome In Adults: Comparing Immediate Release ...  Apr 19, 2006
...the safety profile and to evaluate the clinical benefits (as assessed by efficacy endpoints and patient-reported outcomes) of ropinirole extended release ... - Community Dispatch

PLoS Medicine challenges "disease mongering"  May 5, 2006
GSK has been accused of creating the "restless legs" syndrome as part of its marketing activities around the launch of its Ropinirole drug. ... - Information World Review

SkyePharma PLC - Preliminary Results Announcement for the Year ...  Apr 19, 2006
December 2005, SkyePharma's collaborator GlaxoSmithKline submitted Requip Once-a-day, a once-daily dosage formulation of Requip(R) (ropinirole), for approval ... - PR Newswire

Healthcare: At a Glance - Pharma Firms Slammed for 'Disease ...  Apr 21, 2006
...depression. Indeed - GSK is behind a treatment called Requip (ropinirole), which it hopes to market as Adartrel in the UK. Clew ... - International News Service

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional